CLASS ACTION UPDATE for ADMS, FCAU and GERN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / January 31, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ADMS Shareholders Click Here: https://www.zlk.com/pslra-1/adamas-pharmaceuticals-inc-loss-form?prid=5390&wire=1
FCAU Shareholders Click Here: https://www.zlk.com/pslra-1/fiat-chrysler-automobiles-n-v-loss-form?prid=5390&wire=1
GERN Shareholders Click Here: https://www.zlk.com/pslra-1/geron-corporation-et-al-loss-form?prid=5390&wire=1

* ADDITIONAL INFORMATION BELOW *

Adamas Pharmaceuticals, Inc. (NASDAQGM:ADMS)

ADMS Lawsuit on behalf of: investors who purchased August 8, 2017 – September 30, 2019
Lead Plaintiff Deadline: February 10, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/adamas-pharmaceuticals-inc-loss-form?prid=5390&wire=1

According to the filed complaint, during the class period, Adamas Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" – i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.

Fiat Chrysler Automobiles N.V. (NYSE:FCAU)

FCAU Lawsuit on behalf of: investors who purchased February 26, 2016 – November 20, 2019
Lead Plaintiff Deadline : January 31, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fiat-chrysler-automobiles-n-v-loss-form?prid=5390&wire=1

According to the filed complaint, during the class period, Fiat Chrysler Automobiles N.V. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company employed a bribery scheme to obtain favorable terms in its collective bargaining agreement with United Automobile, Aerospace and Agricultural Implement Workers of America; (2) high-ranking Fiat officials were aware of and authorized the scheme; and (3) as a result, Defendants' statements about Fiat's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Geron Corporation (NASDAQ:GERN)

GERN Lawsuit on behalf of: investors who purchased March 19, 2018 – September 26, 2018
Lead Plaintiff Deadline: March 23, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/geron-corporation-et-al-loss-form?prid=5390&wire=1

The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 574826